Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy.

Darini C, Ghaddar N, Chabot C, Assaker G, Sabri S, Wang S, Krishnamoorthy J, Buchanan M, Aguilar-Mahecha A, Abdulkarim B, Deschenes J, Torres J, Ursini-Siegel J, Basik M, Koromilas AE.

Nat Commun. 2019 May 13;10(1):2139. doi: 10.1038/s41467-019-10138-8.

2.

M(en)TORship lessons on life and death by the integrated stress response.

Koromilas AE.

Biochim Biophys Acta Gen Subj. 2019 Mar;1863(3):644-649. doi: 10.1016/j.bbagen.2018.12.009. Epub 2018 Dec 17. Review.

PMID:
30572003
3.

Downregulation of PERK activity and eIF2α serine 51 phosphorylation by mTOR complex 1 elicits pro-oxidant and pro-death effects in tuberous sclerosis-deficient cells.

Krishnamoorthy J, Tenkerian C, Gupta J, Ghaddar N, Wang S, Darini C, Staschke KA, Ghosh A, Gandin V, Topisirovic I, Kristof AS, Hatzoglou M, Simos G, Koromilas AE.

Cell Death Dis. 2018 Feb 15;9(3):254. doi: 10.1038/s41419-018-0326-2.

4.

Defective interplay between mTORC1 activity and endoplasmic reticulum stress-unfolded protein response in uremic vascular calcification.

Panda DK, Bai X, Sabbagh Y, Zhang Y, Zaun HC, Karellis A, Koromilas AE, Lipman ML, Karaplis AC.

Am J Physiol Renal Physiol. 2018 Jun 1;314(6):F1046-F1061. doi: 10.1152/ajprenal.00350.2017. Epub 2018 Jan 10.

5.

A Unique ISR Program Determines Cellular Responses to Chronic Stress.

Guan BJ, van Hoef V, Jobava R, Elroy-Stein O, Valasek LS, Cargnello M, Gao XH, Krokowski D, Merrick WC, Kimball SR, Komar AA, Koromilas AE, Wynshaw-Boris A, Topisirovic I, Larsson O, Hatzoglou M.

Mol Cell. 2017 Dec 7;68(5):885-900.e6. doi: 10.1016/j.molcel.2017.11.007.

6.

The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression.

Ahn R, Sabourin V, Bolt AM, Hébert S, Totten S, De Jay N, Festa MC, Young YK, Im YK, Pawson T, Koromilas AE, Muller WJ, Mann KK, Kleinman CL, Ursini-Siegel J.

Nat Commun. 2017 Mar 9;8:14638. doi: 10.1038/ncomms14638.

7.

Regulation of ULK1 Expression and Autophagy by STAT1.

Goldberg AA, Nkengfac B, Sanchez AM, Moroz N, Qureshi ST, Koromilas AE, Wang S, Burelle Y, Hussain SN, Kristof AS.

J Biol Chem. 2017 Feb 3;292(5):1899-1909. doi: 10.1074/jbc.M116.771584. Epub 2016 Dec 23.

8.

Protein Kinase R Mediates the Inflammatory Response Induced by Hyperosmotic Stress.

Farabaugh KT, Majumder M, Guan BJ, Jobava R, Wu J, Krokowski D, Gao XH, Schuster A, Longworth M, Chan ED, Bianchi M, Dey M, Koromilas AE, Ramakrishnan P, Hatzoglou M.

Mol Cell Biol. 2017 Feb 1;37(4). pii: e00521-16. doi: 10.1128/MCB.00521-16. Print 2017 Feb 15.

9.
10.

Increased phosphorylation of eIF2α in chronic myeloid leukemia cells stimulates secretion of matrix modifying enzymes.

Podszywalow-Bartnicka P, Cmoch A, Wolczyk M, Bugajski L, Tkaczyk M, Dadlez M, Nieborowska-Skorska M, Koromilas AE, Skorski T, Piwocka K.

Oncotarget. 2016 Nov 29;7(48):79706-79721. doi: 10.18632/oncotarget.12941.

11.

AMP Kinase Activation Alters Oxidant-Induced Stress Granule Assembly by Modulating Cell Signaling and Microtubule Organization.

Mahboubi H, Koromilas AE, Stochaj U.

Mol Pharmacol. 2016 Oct;90(4):460-8. doi: 10.1124/mol.116.105494. Epub 2016 Jul 18.

PMID:
27430620
12.

The eIF2α serine 51 phosphorylation-ATF4 arm promotes HIPPO signaling and cell death under oxidative stress.

Rajesh K, Krishnamoorthy J, Gupta J, Kazimierczak U, Papadakis AI, Deng Z, Wang S, Kuninaka S, Koromilas AE.

Oncotarget. 2016 Aug 9;7(32):51044-51058. doi: 10.18632/oncotarget.10480.

13.

STAT1-mediated translational control in tumor suppression and antitumor therapies.

Wang S, Koromilas AE.

Mol Cell Oncol. 2015 Nov 13;3(3):e1055049. doi: 10.1080/23723556.2015.1055049. eCollection 2016 May.

14.

mTORC1 and CK2 coordinate ternary and eIF4F complex assembly.

Gandin V, Masvidal L, Cargnello M, Gyenis L, McLaughlan S, Cai Y, Tenkerian C, Morita M, Balanathan P, Jean-Jean O, Stambolic V, Trost M, Furic L, Larose L, Koromilas AE, Asano K, Litchfield D, Larsson O, Topisirovic I.

Nat Commun. 2016 Apr 4;7:11127. doi: 10.1038/ncomms11127.

15.

[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.

Booth L, Roberts JL, Tavallai M, Chuckalovcak J, Stringer DK, Koromilas AE, Boone DL, McGuire WP, Poklepovic A, Dent P.

Oncotarget. 2016 Apr 26;7(17):23608-32. doi: 10.18632/oncotarget.8281.

16.

Phosphorylation of eIF2α Is a Translational Control Mechanism Regulating Muscle Stem Cell Quiescence and Self-Renewal.

Zismanov V, Chichkov V, Colangelo V, Jamet S, Wang S, Syme A, Koromilas AE, Crist C.

Cell Stem Cell. 2016 Jan 7;18(1):79-90. doi: 10.1016/j.stem.2015.09.020. Epub 2015 Nov 5.

17.

mTORC2 Balances AKT Activation and eIF2α Serine 51 Phosphorylation to Promote Survival under Stress.

Tenkerian C, Krishnamoorthy J, Mounir Z, Kazimierczak U, Khoutorsky A, Staschke KA, Kristof AS, Wang S, Hatzoglou M, Koromilas AE.

Mol Cancer Res. 2015 Oct;13(10):1377-88. doi: 10.1158/1541-7786.MCR-15-0184-T. Epub 2015 Jun 30.

18.

Stat1 stimulates cap-independent mRNA translation to inhibit cell proliferation and promote survival in response to antitumor drugs.

Wang S, Patsis C, Koromilas AE.

Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):E2149-55. doi: 10.1073/pnas.1420671112. Epub 2015 Apr 13.

19.

Phosphorylation of the translation initiation factor eIF2α at serine 51 determines the cell fate decisions of Akt in response to oxidative stress.

Rajesh K, Krishnamoorthy J, Kazimierczak U, Tenkerian C, Papadakis AI, Wang S, Huang S, Koromilas AE.

Cell Death Dis. 2015 Jan 15;6:e1591. doi: 10.1038/cddis.2014.554.

20.

Roles of the translation initiation factor eIF2α serine 51 phosphorylation in cancer formation and treatment.

Koromilas AE.

Biochim Biophys Acta. 2015 Jul;1849(7):871-80. doi: 10.1016/j.bbagrm.2014.12.007. Epub 2014 Dec 11. Review.

PMID:
25497381
21.

Translational control during endoplasmic reticulum stress beyond phosphorylation of the translation initiation factor eIF2α.

Guan BJ, Krokowski D, Majumder M, Schmotzer CL, Kimball SR, Merrick WC, Koromilas AE, Hatzoglou M.

J Biol Chem. 2014 May 2;289(18):12593-611. doi: 10.1074/jbc.M113.543215. Epub 2014 Mar 19.

22.

Evidence for eIF2α phosphorylation-independent effects of GSK2656157, a novel catalytic inhibitor of PERK with clinical implications.

Krishnamoorthy J, Rajesh K, Mirzajani F, Kesoglidou P, Papadakis AI, Koromilas AE.

Cell Cycle. 2014;13(5):801-6. doi: 10.4161/cc.27726. Epub 2014 Jan 8.

23.

eIF2α phosphorylation bypasses premature senescence caused by oxidative stress and pro-oxidant antitumor therapies.

Rajesh K, Papadakis AI, Kazimierczak U, Peidis P, Wang S, Ferbeyre G, Kaufman RJ, Koromilas AE.

Aging (Albany NY). 2013 Dec;5(12):884-901.

24.

The tumor suppressor function of STAT1 in breast cancer.

Koromilas AE, Sexl V.

JAKSTAT. 2013 Apr 1;2(2):e23353. doi: 10.4161/jkst.23353. Review.

25.

Control of oncogenesis by eIF2α phosphorylation: implications in PTEN and PI3K-Akt signaling and tumor treatment.

Koromilas AE, Mounir Z.

Future Oncol. 2013 Jul;9(7):1005-15. doi: 10.2217/fon.13.49. Review.

PMID:
23837763
26.

A self-defeating anabolic program leads to β-cell apoptosis in endoplasmic reticulum stress-induced diabetes via regulation of amino acid flux.

Krokowski D, Han J, Saikia M, Majumder M, Yuan CL, Guan BJ, Bevilacqua E, Bussolati O, Bröer S, Arvan P, Tchórzewski M, Snider MD, Puchowicz M, Croniger CM, Kimball SR, Pan T, Koromilas AE, Kaufman RJ, Hatzoglou M.

J Biol Chem. 2013 Jun 14;288(24):17202-13. doi: 10.1074/jbc.M113.466920. Epub 2013 May 3.

27.

The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells.

Kusio-Kobialka M, Podszywalow-Bartnicka P, Peidis P, Glodkowska-Mrowka E, Wolanin K, Leszak G, Seferynska I, Stoklosa T, Koromilas AE, Piwocka K.

Cell Cycle. 2012 Nov 1;11(21):4069-78. doi: 10.4161/cc.22387. Epub 2012 Oct 24.

28.

Protein tyrosine phosphatase 1B deficiency potentiates PERK/eIF2α signaling in brown adipocytes.

Bettaieb A, Matsuo K, Matsuo I, Wang S, Melhem R, Koromilas AE, Haj FG.

PLoS One. 2012;7(4):e34412. doi: 10.1371/journal.pone.0034412. Epub 2012 Apr 3.

29.

Alternative ferritin mRNA translation via internal initiation.

Daba A, Koromilas AE, Pantopoulos K.

RNA. 2012 Mar;18(3):547-56. doi: 10.1261/rna.029322.111. Epub 2012 Jan 23. Erratum in: RNA. 2012 Jun;18(6):1307.

30.

Akt determines cell fate through inhibition of the PERK-eIF2α phosphorylation pathway.

Mounir Z, Krishnamoorthy JL, Wang S, Papadopoulou B, Campbell S, Muller WJ, Hatzoglou M, Koromilas AE.

Sci Signal. 2011 Sep 27;4(192):ra62. doi: 10.1126/scisignal.2001630.

31.
32.

Development of transgenic mice expressing a conditionally active form of the eIF2α kinase PKR.

Papadakis AI, Baltzis D, Buensuceso RC, Peidis P, Koromilas AE.

Genesis. 2011 Sep;49(9):743-9. doi: 10.1002/dvg.20749. Epub 2011 Aug 18.

PMID:
21438126
33.

Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation.

Raven JF, Williams V, Wang S, Tremblay ML, Muller WJ, Durbin JE, Koromilas AE.

Cell Cycle. 2011 Mar 1;10(5):794-804. Epub 2011 Mar 1.

PMID:
21311224
34.

HDAC pharmacological inhibition promotes cell death through the eIF2α kinases PKR and GCN2.

Peidis P, Papadakis AI, Rajesh K, Koromilas AE.

Aging (Albany NY). 2010 Oct;2(10):669-77.

35.

eIF2{alpha} Kinase PKR modulates the hypoxic response by Stat3-dependent transcriptional suppression of HIF-1{alpha}.

Papadakis AI, Paraskeva E, Peidis P, Muaddi H, Li S, Raptis L, Pantopoulos K, Simos G, Koromilas AE.

Cancer Res. 2010 Oct 15;70(20):7820-9. doi: 10.1158/0008-5472.CAN-10-0215. Epub 2010 Oct 5.

36.

Phosphorylation of eIF2α at serine 51 is an important determinant of cell survival and adaptation to glucose deficiency.

Muaddi H, Majumder M, Peidis P, Papadakis AI, Holcik M, Scheuner D, Kaufman RJ, Hatzoglou M, Koromilas AE.

Mol Biol Cell. 2010 Sep 15;21(18):3220-31. doi: 10.1091/mbc.E10-01-0023. Epub 2010 Jul 21.

37.

Doxorubicin bypasses the cytoprotective effects of eIF2α phosphorylation and promotes PKR-mediated cell death.

Peidis P, Papadakis AI, Muaddi H, Richard S, Koromilas AE.

Cell Death Differ. 2011 Jan;18(1):145-54. doi: 10.1038/cdd.2010.76. Epub 2010 Jun 18.

38.

Uncovering the PKR pathway's potential for treatment of tumors.

Mounir Z, Koromilas AE.

Future Oncol. 2010 May;6(5):643-5. doi: 10.2217/fon.10.45. Review. No abstract available.

39.

STAT1 represses Skp2 gene transcription to promote p27Kip1 stabilization in Ras-transformed cells.

Wang S, Raven JF, Koromilas AE.

Mol Cancer Res. 2010 May;8(5):798-805. doi: 10.1158/1541-7786.MCR-10-0027. Epub 2010 Apr 20.

40.

eIF2alpha phosphorylation tips the balance to apoptosis during osmotic stress.

Bevilacqua E, Wang X, Majumder M, Gaccioli F, Yuan CL, Wang C, Zhu X, Jordan LE, Scheuner D, Kaufman RJ, Koromilas AE, Snider MD, Holcik M, Hatzoglou M.

J Biol Chem. 2010 May 28;285(22):17098-111. doi: 10.1074/jbc.M110.109439. Epub 2010 Mar 25.

41.

Tumor suppression by PTEN requires the activation of the PKR-eIF2alpha phosphorylation pathway.

Mounir Z, Krishnamoorthy JL, Robertson GP, Scheuner D, Kaufman RJ, Georgescu MM, Koromilas AE.

Sci Signal. 2009 Dec 22;2(102):ra85. doi: 10.1126/scisignal.2000389.

42.

PKR is not a universal target of tumor suppressor p53 in response to genotoxic stress.

Rahman M, Lem C, Muaddi H, Koromilas AE.

Cell Cycle. 2009 Nov 1;8(21):3606-7. Epub 2009 Nov 18.

PMID:
19838063
43.
44.

Stat1 phosphorylation determines Ras oncogenicity by regulating p27 kip1.

Wang S, Raven JF, Durbin JE, Koromilas AE.

PLoS One. 2008;3(10):e3476. doi: 10.1371/journal.pone.0003476. Epub 2008 Oct 22.

45.

IRES-mediated translational control of AMAP1 expression during differentiation of monocyte U937 cells.

Miyata M, Raven JF, Baltzis D, Koromilas AE, Sabe H.

Cell Cycle. 2008 Oct;7(20):3273-81. Epub 2008 Oct 28.

PMID:
18843202
46.

The eIF2alpha kinases inhibit vesicular stomatitis virus replication independently of eIF2alpha phosphorylation.

Krishnamoorthy J, Mounir Z, Raven JF, Koromilas AE.

Cell Cycle. 2008 Aug;7(15):2346-51. Epub 2008 May 21.

PMID:
18677106
47.

PERK and PKR: old kinases learn new tricks.

Raven JF, Koromilas AE.

Cell Cycle. 2008 May 1;7(9):1146-50. Epub 2008 Feb 21. Review.

PMID:
18418049
48.

PKR and PKR-like endoplasmic reticulum kinase induce the proteasome-dependent degradation of cyclin D1 via a mechanism requiring eukaryotic initiation factor 2alpha phosphorylation.

Raven JF, Baltzis D, Wang S, Mounir Z, Papadakis AI, Gao HQ, Koromilas AE.

J Biol Chem. 2008 Feb 8;283(6):3097-108. Epub 2007 Dec 6.

49.

Modulation of the eukaryotic initiation factor 2 alpha-subunit kinase PERK by tyrosine phosphorylation.

Su Q, Wang S, Gao HQ, Kazemi S, Harding HP, Ron D, Koromilas AE.

J Biol Chem. 2008 Jan 4;283(1):469-75. Epub 2007 Nov 12.

50.

The eIF2alpha kinases PERK and PKR activate glycogen synthase kinase 3 to promote the proteasomal degradation of p53.

Baltzis D, Pluquet O, Papadakis AI, Kazemi S, Qu LK, Koromilas AE.

J Biol Chem. 2007 Oct 26;282(43):31675-87. Epub 2007 Sep 4.

Supplemental Content

Loading ...
Support Center